Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug
Launched by UNIVERSITY OF ULSAN · Apr 25, 2013
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult uremic patients with one or more antiplatelet medication,
- • prolonged collagen/epinephrine (CEPI) closure time,
- • need for emergent hemodialysis and
- • subsequent catheter insertion
- Exclusion Criteria:
- • acute coronary syndrome,
- • hemophilia, and nephrogenic diabetes insipidus,
- • allergy against desmopressin
About University Of Ulsan
The University of Ulsan, a prominent research institution in South Korea, is dedicated to advancing healthcare and medical science through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, the university conducts a wide range of clinical trials aimed at evaluating new treatments, therapies, and medical technologies. Leveraging its state-of-the-art facilities and expertise, the University of Ulsan fosters a rigorous research environment that prioritizes patient safety, ethical standards, and the translation of scientific discoveries into clinical practice, ultimately contributing to improved health outcomes and advancements in medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Seoul, Songpa Gu, Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials